ADC Therapeutics
Rue Saint-Pierre 2,
Lausanne
1003
Tel: 1-212-616-4000
Website: http://www.adctherapeutics.com/
Email: info@adctherapeutics.com
195 articles about ADC Therapeutics
-
Severe respiratory problems killed seven patients and affected five others, though the company said that most of these were likely unrelated to the drug.
-
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
7/11/2023
ADC Therapeutics SA announced a voluntary pause in the enrollment of new patients in the Phase 2 LOTIS-9 clinical trial evaluating ZYNLONTA® and rituximab in unfit or frail patients with previously untreated diffuse large B-cell lymphoma.
-
ADC Therapeutics Announces Evolution of Board of Directors
6/15/2023
ADC Therapeutics SA announced the election of Robert W. Azelby to its Board of Directors.
-
ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
6/9/2023
ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA ® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
-
ADC Therapeutics to Participate in the Jefferies Healthcare Conference
6/1/2023
ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on Thursday, June 8th at 8:30 a.m. EDT.
-
ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress
5/11/2023
ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), have been accepted for presentation at the European Hematology Association 2023 Hybrid Congress (EHA2023), which will be held in Frankfurt, Germany from June 8-11, 2023.
-
ADC Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
5/10/2023
ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York City on Tuesday, May 16th at 10:00 a.m. EDT.
-
ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update
5/9/2023
ADC Therapeutics SA reported financial results for the first quarter 2023 and provided an updated corporate strategy.
-
ADC Therapeutics to Host First Quarter 2023 Financial Results Conference Call on May 9, 2023
5/2/2023
ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023 at 8:30 a.m. EDT to report financial results for the first quarter 2023 and provide business updates.
-
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
3/15/2023
ADC Therapeutics SA announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, has been filed with the U.S. Securities and Exchange Commission.
-
ADC Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
3/1/2023
ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the Cowen 43rd Annual Health Care Conference in Boston, MA, on Tuesday, March 7th at 2:50 p.m. ET.
-
ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
2/28/2023
ADC Therapeutics SA today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided business updates.
-
ADC Therapeutics to Host Fourth Quarter and Year-End 2022 Financial Results Conference Call on February 28, 2023
2/21/2023
ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, February 28, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and year-end 2022 and provide business updates.
-
ADC Therapeutics Announces Pricing of Underwritten Offering by a Selling Shareholder
2/2/2023
ADC Therapeutics SA today announced the pricing of an underwritten offering of 12,000,000 common shares of the Company currently owned by A.T. Holdings II Sàrl (the “Selling Shareholder”), an affiliate of Auven Therapeutics Holdings L.P., at a price of $5.00 per share.
-
ADC Therapeutics to Participate in February Investor Conferences
2/1/2023
ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in February.
-
ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 11th at 3:00 p.m. PT.
-
ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer
1/3/2023
ADC Therapeutics SA announced the appointment of industry veteran Mohamed Zaki, MD, PhD, as Chief Medical Officer, effective January 3, 2023. He will serve on the Company’s executive leadership team.
-
ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
12/21/2022
ADC Therapeutics SA and Swedish Orphan Biovitrum AB announced the European Commission has granted conditional marketing authorization for the use of ZYNLONTA® for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
-
ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer
12/19/2022
ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022.
-
Biocytogen Enters into Antibody Agreement with ADC Therapeutics
11/28/2022
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA.